A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage (Rm) Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Trial Profile

A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage (Rm) Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Dapagliflozin (Primary) ; Dapagliflozin/metformin (Primary) ; Metformin (Primary)
  • Indications Diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 08 Mar 2013 Planned End Date changed from 1 Jun 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top